{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:02:36Z","timestamp":1794283356260,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01256-2","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:29:08Z","timestamp":1743222548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-6012","authenticated-orcid":false,"given":"Sharlene","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-6316","authenticated-orcid":false,"given":"Adeel M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-2935","authenticated-orcid":false,"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anosheh","family":"Afghahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1256_CR1","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487\u201398.","journal-title":"N Engl J Med"},{"key":"1256_CR2","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","volume":"114","author":"F Parlati","year":"2009","unstructured":"Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114:3439\u201347.","journal-title":"Blood"},{"key":"1256_CR3","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383\u201391.","journal-title":"Cancer Res"},{"key":"1256_CR4","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281\u201390.","journal-title":"Blood"},{"key":"1256_CR5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"S David","year":"2013","unstructured":"David S, Thomas M, Ajay N, Harvey RD, Ravi V, Ruben N, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753\u201361.","journal-title":"Haematologica"},{"key":"1256_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"1256_CR7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327\u201337.","journal-title":"Lancet Oncol"},{"key":"1256_CR8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"1256_CR9","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7:3739\u201348.","journal-title":"Blood Adv"},{"key":"1256_CR10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361\u201371.","journal-title":"Lancet"},{"key":"1256_CR11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/10428194.2024.2322030","volume":"65","author":"A Perrot","year":"2024","unstructured":"Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, et al. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma. 2024;65:833\u201342.","journal-title":"Leuk Lymphoma"},{"key":"1256_CR12","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817\u201325.","journal-title":"Blood"},{"key":"1256_CR13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","volume":"12","author":"S Jagannath","year":"2012","unstructured":"Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12:310\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1256_CR14","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-19-1997","volume":"26","author":"S Ailawadhi","year":"2020","unstructured":"Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res. 2020;26:3969\u201378.","journal-title":"Clin Cancer Res"},{"key":"1256_CR15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953\u201364.","journal-title":"Lancet Oncol"},{"key":"1256_CR16","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Coriu D, Delimpasi S, Spicka I, Upchurch TE, Fang B, et al. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma. Blood Adv. 2024. https:\/\/doi.org\/10.1182\/bloodadvances.2024013101.","DOI":"10.1182\/bloodadvances.2024013101"},{"key":"1256_CR17","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1256_CR18","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"Lancet Haematol"},{"key":"1256_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Rosi\u00f1ol L, van der Klift M, Mina R, et al. Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142:4.","journal-title":"Blood"},{"key":"1256_CR20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1256_CR21","volume":"14","author":"FW Hoff","year":"2024","unstructured":"Hoff FW, Banerjee R, Khan AM, McCaughan G, Wang B, Wang X, et al. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. Blood Cancer J. 2024;14:52.","journal-title":"Blood Cancer J"},{"key":"1256_CR22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/10781552211015283","volume":"28","author":"N Raje","year":"2022","unstructured":"Raje N, Medhekar R, Panjabi S, Hines DM, Wang X, Iskander K, et al. Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. J Oncol Pharm Pract. 2022;28:1130\u20139.","journal-title":"J Oncol Pharm Pract"},{"key":"1256_CR23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2024.02.013","volume":"24","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Cowan AJ, Ortega M, Missimer C, Carpenter PA, Oshima MU, et al. Financial toxicity, time toxicity, and quality of life in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:446\u201354.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1256_CR24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2024.2352086","volume":"65","author":"M Di","year":"2024","unstructured":"Di M, Su CT, Cowan AJ, Gopal AK, Banerjee R. Mitigating time toxicity in lymphoma and multiple myeloma. Leuk Lymphoma. 2024;65:1418\u201329.","journal-title":"Leuk Lymphoma"},{"key":"1256_CR25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ajh.25498","volume":"94","author":"N Biran","year":"2019","unstructured":"Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, et al. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019;94:794\u2013802.","journal-title":"Am J Hematol"},{"key":"1256_CR26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"1256_CR27","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2023.41.16_suppl.8001","volume":"41","author":"A Nooka","year":"2023","unstructured":"Nooka A, Joseph N, Dhodapkar M, Hofmeister C, Gupta V, Andrews J, et al. Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in. J Clin Oncol. 2023;41:8001.","journal-title":"J Clin Oncol"},{"key":"1256_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01129-0","volume":"14","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Biru Y, Cole CE, Faiman B, Midha S, Ailawadhi S. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer J. 2024;14:149.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01256-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01256-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:30:10Z","timestamp":1743222610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01256-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01256-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4839164\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RB: Consulting: Adaptive, BMS, Caribou Biosciences, Genentech, Gilead\/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. AMK: Research: Sanofi, Janssen. XW: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. MW: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. AA: Employment: Flatiron Health, Inc. (independent subsidiary of the Roche Group), stock ownership, Roche. MJ: Consulting: Janssen, BMS, Legend. Research: Janssen, BMS, Fate Therapeutics. ASS: Consulting: Novartis. LDA Jr: Consulting: Janssen, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena. Research: BMS, Celgene, GSK, Janssen, Abbvie. AJC: Consulting: BMS, Adaptive; Research: Adaptive Biotechnologies, Harpoon, Nektar, BMS, Janssen, Sanofi, AbbVie. GK: Consulting: BMS, Arcellx, Sanofi, Janssen, Cellectar, Pfizer, Kedrion; Research: BMS, Janssen, Abbvie. GK: Consulting: BMS, Arcellx, Sanofi, Janssen, Cellectar, Pfizer, Kedrion, Kite; Research: BMS, Janssen, Abbvie, Arcellx. The remaining authors have no disclosures to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This retrospective study was reviewed and exempted by the University of Texas Southwestern Institutional Review Board without the need for individual patient consent. No patient-identifiable information was shared during analyses or are present in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"48"}}